Tetrandrine decreases Mtb antigen presentation. by Elham Karamooz (2584474)

HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

ATGL-1 levels increase and lipid droplets decrease in response to <i>N. parisii</i> infection. by Hala Tamim El Jarkass (16625309)

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…(f) A second group of mice followed the same procedures but without experiencing daily restraint stress (<i>N</i> = 3 mice, <i>n</i> = 123 neurons). These mice exhibited a minimal change in noise-evoked PPy activity when comparing the first and second week of imaging (2-way ANOVA, F = 1.79, <i>p</i> = 0.11, post hoc baseline w1 50 dB: baseline w2 50 dB <i>p</i> = 1 Bonferroni corrected, nested ANOVA (mouse nested within session) F = 1.76, <i>p</i> = 0.12, mean ± SE). …”

Functional analysis of a <i>kh</i>^<i>w</i> mutant mosquitoes. by Si Yu Zhao (19544793)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

<i>trusRNAi</i> induced with various wing disc drivers affects wing size and morphology and decreases cellular proliferation. by Saeko Takada (21616085)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

Skin marks is the S1 Fig title. by Mercedes Soto-González (20422078)

“…</p><p>Results</p><p>The IRD decreased after both exercise programs compared to baseline measurements in AB2 (mean difference: 3.06 mm, 95% CI: 1.06 to 5.05) and in AB5 (mean difference: 2.88 mm, 95% CI: 1.59 to 4.17), confirming the long-term effect of exercise. …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Nitrogen enrichment decreases the functional and compositional stability of alpine meadow community by different mechanisms by Yang Xiangrong (22802927)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects: